-
1
-
-
84861543083
-
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
-
Chalasani N., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55(6):2005-2023.
-
(2012)
Hepatology
, vol.55
, Issue.6
, pp. 2005-2023
-
-
Chalasani, N.1
-
2
-
-
77950323927
-
Pathogenesis of non-alcoholic fatty liver disease
-
Dowman J.K., Tomlinson J.W., Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease. Qjm 2010, 103(2):71-83.
-
(2010)
Qjm
, vol.103
, Issue.2
, pp. 71-83
-
-
Dowman, J.K.1
Tomlinson, J.W.2
Newsome, P.N.3
-
3
-
-
75449102165
-
Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?
-
Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010, 51(2):373-375.
-
(2010)
Hepatology
, vol.51
, Issue.2
, pp. 373-375
-
-
Angulo, P.1
-
4
-
-
84888439070
-
Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease
-
Chang E., Park C.Y., Park S.W. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J.Diabetes Investig. 2013, 4(6):517-524.
-
(2013)
J.Diabetes Investig.
, vol.4
, Issue.6
, pp. 517-524
-
-
Chang, E.1
Park, C.Y.2
Park, S.W.3
-
5
-
-
84872765906
-
Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?
-
Ahmed M.H., Barakat S., Almobarak A.O. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists?. J.Obes. 2012, 2012:483135.
-
(2012)
J.Obes.
, vol.2012
, pp. 483135
-
-
Ahmed, M.H.1
Barakat, S.2
Almobarak, A.O.3
-
6
-
-
84881478224
-
Non-alcoholic fatty liver disease and cardiovascular risk
-
Brea A., Puzo J. Non-alcoholic fatty liver disease and cardiovascular risk. Int. J. Cardiol. 2013, 167(4):1109-1117.
-
(2013)
Int. J. Cardiol.
, vol.167
, Issue.4
, pp. 1109-1117
-
-
Brea, A.1
Puzo, J.2
-
7
-
-
53549112749
-
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?
-
Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. Diabetologia 2008, 51(11):1947-1953.
-
(2008)
Diabetologia
, vol.51
, Issue.11
, pp. 1947-1953
-
-
Targher, G.1
Marra, F.2
Marchesini, G.3
-
8
-
-
84896690517
-
Extrahepatic complications of nonalcoholic fatty liver disease
-
Armstrong M.J., et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2014, 59(3):1174-1197.
-
(2014)
Hepatology
, vol.59
, Issue.3
, pp. 1174-1197
-
-
Armstrong, M.J.1
-
9
-
-
79960029926
-
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults
-
Vernon G., Baranova A., Younossi Z.M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34(3):274-285.
-
(2011)
Aliment. Pharmacol. Ther.
, vol.34
, Issue.3
, pp. 274-285
-
-
Vernon, G.1
Baranova, A.2
Younossi, Z.M.3
-
10
-
-
0025260531
-
Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors
-
Wanless I.R., Lentz J.S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12(5):1106-1110.
-
(1990)
Hepatology
, vol.12
, Issue.5
, pp. 1106-1110
-
-
Wanless, I.R.1
Lentz, J.S.2
-
11
-
-
79956062113
-
Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study
-
Williamson R.M., et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh type 2 diabetes Study. Diabetes Care 2011, 34(5):1139-1144.
-
(2011)
Diabetes Care
, vol.34
, Issue.5
, pp. 1139-1144
-
-
Williamson, R.M.1
-
12
-
-
33748110788
-
Hepatic histology in obese patients undergoing bariatric surgery
-
Machado M., Marques-Vidal P., Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J.Hepatol. 2006, 45(4):600-606.
-
(2006)
J.Hepatol.
, vol.45
, Issue.4
, pp. 600-606
-
-
Machado, M.1
Marques-Vidal, P.2
Cortez-Pinto, H.3
-
13
-
-
84877854022
-
Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease
-
Gaggini M., et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients 2013, 5(5):1544-1560.
-
(2013)
Nutrients
, vol.5
, Issue.5
, pp. 1544-1560
-
-
Gaggini, M.1
-
14
-
-
84876522373
-
Current concepts and management approaches in nonalcoholic fatty liver disease
-
Attar B.M., Van Thiel D.H. Current concepts and management approaches in nonalcoholic fatty liver disease. Sci. World J. 2013, 2013:481893.
-
(2013)
Sci. World J.
, vol.2013
, pp. 481893
-
-
Attar, B.M.1
Van Thiel, D.H.2
-
15
-
-
10644220306
-
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
-
Browning J.D., et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 2004, 40(6):1387-1395.
-
(2004)
Hepatology
, vol.40
, Issue.6
, pp. 1387-1395
-
-
Browning, J.D.1
-
16
-
-
84857429228
-
Ethnicity and nonalcoholic fatty liver disease
-
Bambha K., et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 2012, 55(3):769-780.
-
(2012)
Hepatology
, vol.55
, Issue.3
, pp. 769-780
-
-
Bambha, K.1
-
17
-
-
33750606061
-
Long-term follow-up of patients with NAFLD and elevated liver enzymes
-
Ekstedt M., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44(4):865-873.
-
(2006)
Hepatology
, vol.44
, Issue.4
, pp. 865-873
-
-
Ekstedt, M.1
-
18
-
-
67649306197
-
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
-
Argo C.K., Al-Osaimi A.M., Caldwell S.H. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J.Hepatol. 2009, 51(2):371-379. http://www.ncbi.nlm.nih.gov/pubmed/?term=Northup%20PG%5BAuthor%5D%26cauthor=true%26cauthor_uid=19501928.
-
(2009)
J.Hepatol.
, vol.51
, Issue.2
, pp. 371-379
-
-
Argo, C.K.1
Al-Osaimi, A.M.2
Caldwell, S.H.3
-
19
-
-
84907969087
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia
-
Perazzo H., et al. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Aliment. Pharmacol. Ther. 2014, 40(9):1081-1093.
-
(2014)
Aliment. Pharmacol. Ther.
, vol.40
, Issue.9
, pp. 1081-1093
-
-
Perazzo, H.1
-
20
-
-
79960215555
-
Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period
-
Hamabe A., et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. J.Gastroenterol. 2011, 46(6):769-778.
-
(2011)
J.Gastroenterol.
, vol.46
, Issue.6
, pp. 769-778
-
-
Hamabe, A.1
-
21
-
-
46249090385
-
Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease
-
Dunn W., Xu R., Schwimmer J.B. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008, 47(6):1947-1954.
-
(2008)
Hepatology
, vol.47
, Issue.6
, pp. 1947-1954
-
-
Dunn, W.1
Xu, R.2
Schwimmer, J.B.3
-
22
-
-
84896879418
-
Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease
-
Stanković M.N., et al. Time-dependent changes and association between liver free fatty acids, serum lipid profile and histological features in mice model of nonalcoholic fatty liver disease. Arch. Med. Res. 2014, 45(2):116-124.
-
(2014)
Arch. Med. Res.
, vol.45
, Issue.2
, pp. 116-124
-
-
Stanković, M.N.1
-
23
-
-
67651173053
-
Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers
-
Edens M.A., Kuipers F., Stolk R.P. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes. Rev. 2009, 10(4):412-419.
-
(2009)
Obes. Rev.
, vol.10
, Issue.4
, pp. 412-419
-
-
Edens, M.A.1
Kuipers, F.2
Stolk, R.P.3
-
24
-
-
77957375969
-
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
-
Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N.Engl. J. Med. 2010, 363(14):1341-1350.
-
(2010)
N.Engl. J. Med.
, vol.363
, Issue.14
, pp. 1341-1350
-
-
Targher, G.1
Day, C.P.2
Bonora, E.3
-
25
-
-
79151478841
-
Nonalcoholic fatty liver disease and the coronary artery disease
-
Treeprasertsuk S., Lopez-Jimenez F., Lindor K.D. Nonalcoholic fatty liver disease and the coronary artery disease. Dig. Dis. Sci. 2011, 56(1):35-45.
-
(2011)
Dig. Dis. Sci.
, vol.56
, Issue.1
, pp. 35-45
-
-
Treeprasertsuk, S.1
Lopez-Jimenez, F.2
Lindor, K.D.3
-
26
-
-
0031947715
-
Steatohepatitis: a tale of two "hits"?
-
Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114(4):842-845.
-
(1998)
Gastroenterology
, vol.114
, Issue.4
, pp. 842-845
-
-
Day, C.P.1
James, O.F.2
-
27
-
-
0037153158
-
Acentral role for JNK in obesity and insulin resistance
-
Hirosumi J., et al. Acentral role for JNK in obesity and insulin resistance. Nature 2002, 420(6913):333-336.
-
(2002)
Nature
, vol.420
, Issue.6913
, pp. 333-336
-
-
Hirosumi, J.1
-
28
-
-
14644427890
-
Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB
-
Cai D., et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 2005, 11(2):183-190.
-
(2005)
Nat. Med.
, vol.11
, Issue.2
, pp. 183-190
-
-
Cai, D.1
-
29
-
-
84867692901
-
Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences
-
Del Ben M., et al. Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences. Intern Emerg. Med. 2012, 7(Suppl.3):S291-S296.
-
(2012)
Intern Emerg. Med.
, vol.7
, Issue.SUPPL.3
, pp. S291-S296
-
-
Del Ben, M.1
-
30
-
-
0033231294
-
Association of nonalcoholic fatty liver disease with insulin resistance
-
Marchesini G., et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999, 107(5):450-455.
-
(1999)
Am. J. Med.
, vol.107
, Issue.5
, pp. 450-455
-
-
Marchesini, G.1
-
31
-
-
38649110496
-
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis
-
Biddinger S.B., et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell. Metab. 2008, 7(2):125-134.
-
(2008)
Cell. Metab.
, vol.7
, Issue.2
, pp. 125-134
-
-
Biddinger, S.B.1
-
32
-
-
38649116056
-
Selective versus total insulin resistance: a pathogenic paradox
-
Brown M.S., Goldstein J.L. Selective versus total insulin resistance: a pathogenic paradox. Cell. Metab. 2008, 7(2):95-96.
-
(2008)
Cell. Metab.
, vol.7
, Issue.2
, pp. 95-96
-
-
Brown, M.S.1
Goldstein, J.L.2
-
33
-
-
77953766314
-
Non-alcoholic fatty liver disease proteomics
-
Rodriguez-Suarez E., et al. Non-alcoholic fatty liver disease proteomics. Proteomics Clin. Appl. 2010, 4(4):362-371.
-
(2010)
Proteomics Clin. Appl.
, vol.4
, Issue.4
, pp. 362-371
-
-
Rodriguez-Suarez, E.1
-
34
-
-
84904395679
-
Proteomic and genomic studies of non-alcoholic fatty liver disease-clues in the pathogenesis
-
Lim J.W., Dillon J., Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease-clues in the pathogenesis. World J. Gastroenterol. 2014, 20(26):8325-8340.
-
(2014)
World J. Gastroenterol.
, vol.20
, Issue.26
, pp. 8325-8340
-
-
Lim, J.W.1
Dillon, J.2
Miller, M.3
-
35
-
-
77957302090
-
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c
-
Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes. Metab. 2010, 12(Suppl.2):83-92.
-
(2010)
Diabetes Obes. Metab.
, vol.12
, Issue.SUPPL.2
, pp. 83-92
-
-
Ferre, P.1
Foufelle, F.2
-
36
-
-
84874600898
-
De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health
-
Eissing L., et al. De novo lipogenesis in human fat and liver is linked to ChREBP-beta and metabolic health. Nat. Commun. 2013, 4:1528.
-
(2013)
Nat. Commun.
, vol.4
, pp. 1528
-
-
Eissing, L.1
-
37
-
-
79955121832
-
Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes
-
Wu M., et al. Antidiabetic and antisteatotic effects of the selective fatty acid synthase (FAS) inhibitor platensimycin in mouse models of diabetes. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(13):5378-5383.
-
(2011)
Proc. Natl. Acad. Sci. U. S. A.
, vol.108
, Issue.13
, pp. 5378-5383
-
-
Wu, M.1
-
38
-
-
84907386500
-
Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease
-
Shulman G.I. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N.Engl. J. Med. 2014, 371(12):1131-1141.
-
(2014)
N.Engl. J. Med.
, vol.371
, Issue.12
, pp. 1131-1141
-
-
Shulman, G.I.1
-
39
-
-
46449131992
-
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis
-
Loria P., Lonardo A., Targher G. Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. Clin. Sci. Lond. 2008, 115(1):1-12.
-
(2008)
Clin. Sci. Lond.
, vol.115
, Issue.1
, pp. 1-12
-
-
Loria, P.1
Lonardo, A.2
Targher, G.3
-
40
-
-
0038509036
-
Lipotoxicity: when tissues overeat
-
Schaffer J.E. Lipotoxicity: when tissues overeat. Curr. Opin. Lipidol. 2003, 14(3):281-287.
-
(2003)
Curr. Opin. Lipidol.
, vol.14
, Issue.3
, pp. 281-287
-
-
Schaffer, J.E.1
-
41
-
-
0035912744
-
Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance
-
Kim J.K., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(13):7522-7527.
-
(2001)
Proc. Natl. Acad. Sci. U. S. A.
, vol.98
, Issue.13
, pp. 7522-7527
-
-
Kim, J.K.1
-
42
-
-
0035032163
-
Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance
-
Ferreira L.D., et al. Overexpressing human lipoprotein lipase in mouse skeletal muscle is associated with insulin resistance. Diabetes 2001, 50(5):1064-1068.
-
(2001)
Diabetes
, vol.50
, Issue.5
, pp. 1064-1068
-
-
Ferreira, L.D.1
-
43
-
-
0022552278
-
Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver
-
Bouwens L., et al. Quantitation, tissue distribution and proliferation kinetics of Kupffer cells in normal rat liver. Hepatology 1986, 6(4):718-722.
-
(1986)
Hepatology
, vol.6
, Issue.4
, pp. 718-722
-
-
Bouwens, L.1
-
44
-
-
0026721306
-
Evidence for Kupffer cell migration along liver sinusoids, from high-resolution invivo microscopy
-
MacPhee P.J., Schmidt E.E., Groom A.C. Evidence for Kupffer cell migration along liver sinusoids, from high-resolution invivo microscopy. Am. J. Physiol. 1992, 263(1 Pt 1):G17-G23.
-
(1992)
Am. J. Physiol.
, vol.263
, Issue.1
, pp. G17-G23
-
-
MacPhee, P.J.1
Schmidt, E.E.2
Groom, A.C.3
-
45
-
-
34548272744
-
Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis
-
Rivera C.A., et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J.Hepatol. 2007, 47(4):571-579.
-
(2007)
J.Hepatol.
, vol.47
, Issue.4
, pp. 571-579
-
-
Rivera, C.A.1
-
46
-
-
75449101395
-
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity
-
Stienstra R., et al. Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. Hepatology 2010, 51(2):511-522.
-
(2010)
Hepatology
, vol.51
, Issue.2
, pp. 511-522
-
-
Stienstra, R.1
-
47
-
-
67349205002
-
Kupffer cells in non-alcoholic fatty liver disease: the emerging view
-
Baffy G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J.Hepatol. 2009, 51(1):212-223.
-
(2009)
J.Hepatol.
, vol.51
, Issue.1
, pp. 212-223
-
-
Baffy, G.1
-
48
-
-
33947261669
-
Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients
-
Park J.W., et al. Predictors reflecting the pathological severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J.Gastroenterol. Hepatol. 2007, 22(4):491-497.
-
(2007)
J.Gastroenterol. Hepatol.
, vol.22
, Issue.4
, pp. 491-497
-
-
Park, J.W.1
-
49
-
-
0033789518
-
Adipose tissue as an endocrine organ
-
Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000, 11(8):327-332.
-
(2000)
Trends Endocrinol. Metab.
, vol.11
, Issue.8
, pp. 327-332
-
-
Ahima, R.S.1
Flier, J.S.2
-
50
-
-
0042165989
-
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
-
Feldstein A.E., et al. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003, 125(2):437-443.
-
(2003)
Gastroenterology
, vol.125
, Issue.2
, pp. 437-443
-
-
Feldstein, A.E.1
-
51
-
-
0348134733
-
Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice
-
Feldstein A.E., et al. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J.Hepatol. 2003, 39(6):978-983.
-
(2003)
J.Hepatol.
, vol.39
, Issue.6
, pp. 978-983
-
-
Feldstein, A.E.1
-
52
-
-
42949086433
-
Cellular and molecular mechanisms of liver injury
-
Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134(6):1641-1654.
-
(2008)
Gastroenterology
, vol.134
, Issue.6
, pp. 1641-1654
-
-
Malhi, H.1
Gores, G.J.2
-
53
-
-
84887553152
-
PNPLA3 I148M polymorphism and progressive liver disease
-
Dongiovanni P., et al. PNPLA3 I148M polymorphism and progressive liver disease. World J. Gastroenterol. 2013, 19(41):6969-6978.
-
(2013)
World J. Gastroenterol.
, vol.19
, Issue.41
, pp. 6969-6978
-
-
Dongiovanni, P.1
-
54
-
-
79953745343
-
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits
-
Speliotes E.K., et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011, 7(3):e1001324.
-
(2011)
PLoS Genet.
, vol.7
, Issue.3
, pp. e1001324
-
-
Speliotes, E.K.1
-
55
-
-
56749096610
-
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
-
Romeo S., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 2008, 40(12):1461-1465.
-
(2008)
Nat. Genet.
, vol.40
, Issue.12
, pp. 1461-1465
-
-
Romeo, S.1
-
56
-
-
67349174005
-
Acommon variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans
-
Kotronen A., et al. Acommon variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 2009, 52(6):1056-1060.
-
(2009)
Diabetologia
, vol.52
, Issue.6
, pp. 1056-1060
-
-
Kotronen, A.1
-
57
-
-
79957462315
-
Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease
-
Sookoian S., Pirola C.J. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011, 53(6):1883-1894.
-
(2011)
Hepatology
, vol.53
, Issue.6
, pp. 1883-1894
-
-
Sookoian, S.1
Pirola, C.J.2
-
58
-
-
78049457761
-
Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease
-
1576.e1-6
-
Chalasani N., et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139(5):1567-1576. 1576.e1-6.
-
(2010)
Gastroenterology
, vol.139
, Issue.5
, pp. 1567-1576
-
-
Chalasani, N.1
-
59
-
-
84857398069
-
Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents
-
Santoro N., et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012, 55(3):781-789.
-
(2012)
Hepatology
, vol.55
, Issue.3
, pp. 781-789
-
-
Santoro, N.1
-
60
-
-
84874171496
-
Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects
-
Fu D., et al. Genetic polymorphism of glucokinase on the risk of type 2 diabetes and impaired glucose regulation: evidence based on 298,468 subjects. PLoS One 2013, 8(2):e55727.
-
(2013)
PLoS One
, vol.8
, Issue.2
, pp. e55727
-
-
Fu, D.1
-
61
-
-
84919385811
-
The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease
-
Ferolla S.M., et al. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. Nutrients 2014, 6(12):5583-5599.
-
(2014)
Nutrients
, vol.6
, Issue.12
, pp. 5583-5599
-
-
Ferolla, S.M.1
-
62
-
-
84888023932
-
Obesity and NAFLD: the role of bacteria and microbiota
-
Duseja A., Chawla Y.K. Obesity and NAFLD: the role of bacteria and microbiota. Clin. Liver Dis. 2014, 18(1):59-71.
-
(2014)
Clin. Liver Dis.
, vol.18
, Issue.1
, pp. 59-71
-
-
Duseja, A.1
Chawla, Y.K.2
-
63
-
-
84916218639
-
Probiotics and nonalcoholic fatty liver disease
-
Eslamparast T., et al. Probiotics and nonalcoholic fatty liver disease. Middle East J. Dig. Dis. 2013, 5(3):129-136.
-
(2013)
Middle East J. Dig. Dis.
, vol.5
, Issue.3
, pp. 129-136
-
-
Eslamparast, T.1
-
64
-
-
0029874138
-
The NF-kappa B and I kappa B proteins: new discoveries and insights
-
Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev. Immunol. 1996, 14:649-683.
-
(1996)
Annu Rev. Immunol.
, vol.14
, pp. 649-683
-
-
Baldwin, A.S.1
-
65
-
-
84856957894
-
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
-
Henao-Mejia J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482(7384):179-185.
-
(2012)
Nature
, vol.482
, Issue.7384
, pp. 179-185
-
-
Henao-Mejia, J.1
-
66
-
-
84879604697
-
Intestinal microbiota in patients with nonalcoholic fatty liver disease
-
Mouzaki M., et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 2013, 58(1):120-127.
-
(2013)
Hepatology
, vol.58
, Issue.1
, pp. 120-127
-
-
Mouzaki, M.1
-
67
-
-
84922614287
-
Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
-
Jiang C., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J.Clin. Invest 2014.
-
(2014)
J.Clin. Invest
-
-
Jiang, C.1
-
68
-
-
84894234723
-
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease
-
Ballestri S., et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(7):1724-1745.
-
(2014)
World J. Gastroenterol.
, vol.20
, Issue.7
, pp. 1724-1745
-
-
Ballestri, S.1
-
69
-
-
80051552944
-
Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation
-
Ndumele C.E., et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31(8):1927-1932.
-
(2011)
Arterioscler. Thromb. Vasc. Biol.
, vol.31
, Issue.8
, pp. 1927-1932
-
-
Ndumele, C.E.1
-
70
-
-
84894286316
-
Prothrombotic factors in histologically proven NAFLD and NASH
-
Verrijken A., et al. Prothrombotic factors in histologically proven NAFLD and NASH. Hepatology 2013, 59:121-129.
-
(2013)
Hepatology
, vol.59
, pp. 121-129
-
-
Verrijken, A.1
-
71
-
-
34547596738
-
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
-
Yoneda M., et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J.Gastroenterol. 2007, 42(7):573-582.
-
(2007)
J.Gastroenterol.
, vol.42
, Issue.7
, pp. 573-582
-
-
Yoneda, M.1
-
72
-
-
84922640340
-
High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and Stenosis Burden: results from the ROMICAT II trial
-
Puchner S.B., et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and Stenosis Burden: results from the ROMICAT II trial. Radiology 2014, 140933.
-
(2014)
Radiology
, pp. 140933
-
-
Puchner, S.B.1
-
73
-
-
84928209634
-
Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up
-
(Epub ahead of print)
-
Ekstedt M., et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27368.
-
(2014)
Hepatology
-
-
Ekstedt, M.1
-
74
-
-
84921487729
-
TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease
-
(Epub ahead of print)
-
Dongiovanni P., et al. TM6SF2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27490.
-
(2014)
Hepatology
-
-
Dongiovanni, P.1
-
75
-
-
33746421488
-
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease
-
Targher G., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29(6):1325-1330.
-
(2006)
Diabetes Care
, vol.29
, Issue.6
, pp. 1325-1330
-
-
Targher, G.1
-
76
-
-
84872339818
-
Assessment of endothelial function in patients with nonalcoholic fatty liver disease
-
Colak Y., et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 2013, 43(1):100-107.
-
(2013)
Endocrine
, vol.43
, Issue.1
, pp. 100-107
-
-
Colak, Y.1
-
77
-
-
77954423206
-
Association between nonalcoholic fatty liver disease and coronary artery calcification
-
Chen C.H., et al. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig. Dis. Sci. 2010, 55(6):1752-1760.
-
(2010)
Dig. Dis. Sci.
, vol.55
, Issue.6
, pp. 1752-1760
-
-
Chen, C.H.1
-
78
-
-
84874109849
-
Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey
-
Sirota J.C., et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 2013, 62(3):392-399.
-
(2013)
Metabolism
, vol.62
, Issue.3
, pp. 392-399
-
-
Sirota, J.C.1
-
79
-
-
65249087389
-
SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle
-
Nakagawa T., et al. SIRT5 Deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle. Cell 2009, 137(3):560-570.
-
(2009)
Cell
, vol.137
, Issue.3
, pp. 560-570
-
-
Nakagawa, T.1
-
80
-
-
84891760409
-
Sugar, uric acid, and the etiology of diabetes and obesity
-
Johnson R.J., et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013, 62(10):3307-3315.
-
(2013)
Diabetes
, vol.62
, Issue.10
, pp. 3307-3315
-
-
Johnson, R.J.1
-
81
-
-
77952680758
-
Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study
-
Speliotes E.K., et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology 2010, 51(6):1979-1987.
-
(2010)
Hepatology
, vol.51
, Issue.6
, pp. 1979-1987
-
-
Speliotes, E.K.1
-
82
-
-
20944450486
-
Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms
-
Bugianesi E., et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005, 48(4):634-642.
-
(2005)
Diabetologia
, vol.48
, Issue.4
, pp. 634-642
-
-
Bugianesi, E.1
-
83
-
-
84875615668
-
Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects
-
Choe Y.G., et al. Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects. J.Gastroenterol. Hepatol. 2013, 28(4):678-683.
-
(2013)
J.Gastroenterol. Hepatol.
, vol.28
, Issue.4
, pp. 678-683
-
-
Choe, Y.G.1
-
84
-
-
80052741269
-
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?
-
Maurantonio M., et al. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk?. Arch. Med. Res. 2011, 42(5):337-353.
-
(2011)
Arch. Med. Res.
, vol.42
, Issue.5
, pp. 337-353
-
-
Maurantonio, M.1
-
85
-
-
83555165946
-
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
-
Armstrong M.J., et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J.Hepatol. 2012, 56(1):234-240.
-
(2012)
J.Hepatol.
, vol.56
, Issue.1
, pp. 234-240
-
-
Armstrong, M.J.1
-
86
-
-
84857046691
-
Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography
-
Wong V.W., et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61(3):409-415.
-
(2012)
Gut
, vol.61
, Issue.3
, pp. 409-415
-
-
Wong, V.W.1
-
87
-
-
84922363507
-
Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging
-
Dyson J.K., Anstee Q.M., McPherson S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 2014, 5(3):211-218.
-
(2014)
Frontline Gastroenterol.
, vol.5
, Issue.3
, pp. 211-218
-
-
Dyson, J.K.1
Anstee, Q.M.2
McPherson, S.3
-
88
-
-
84883759656
-
Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD)
-
Verma S., et al. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013, 33(9):1398-1405.
-
(2013)
Liver Int.
, vol.33
, Issue.9
, pp. 1398-1405
-
-
Verma, S.1
-
89
-
-
84898640575
-
Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy
-
Karlas T., et al. Non-invasive assessment of hepatic steatosis in patients with NAFLD using controlled attenuation parameter and 1H-MR spectroscopy. PLoS One 2014, 9(3):e91987.
-
(2014)
PLoS One
, vol.9
, Issue.3
, pp. e91987
-
-
Karlas, T.1
-
90
-
-
84898827951
-
Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations
-
de Ledinghen V., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J.Hepatol. 2014, 60(5):1026-1031.
-
(2014)
J.Hepatol.
, vol.60
, Issue.5
, pp. 1026-1031
-
-
de Ledinghen, V.1
-
91
-
-
84890569059
-
Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease
-
Banerjee R., et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J.Hepatol. 2014, 60(1):69-77.
-
(2014)
J.Hepatol.
, vol.60
, Issue.1
, pp. 69-77
-
-
Banerjee, R.1
-
92
-
-
84880029856
-
MR fat fraction mapping: a simple biomarker for liver steatosis quantification in nonalcoholic fatty liver disease patients
-
Leitao H.S., et al. MR fat fraction mapping: a simple biomarker for liver steatosis quantification in nonalcoholic fatty liver disease patients. Acad. Radiol. 2013, 20(8):957-961.
-
(2013)
Acad. Radiol.
, vol.20
, Issue.8
, pp. 957-961
-
-
Leitao, H.S.1
-
93
-
-
77956119396
-
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
-
McPherson S., et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59(9):1265-1269.
-
(2010)
Gut
, vol.59
, Issue.9
, pp. 1265-1269
-
-
McPherson, S.1
-
94
-
-
79251524594
-
Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis
-
Dowman J.K., Tomlinson J.W., Newsome P.N. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2011, 33(5):525-540.
-
(2011)
Aliment. Pharmacol. Ther.
, vol.33
, Issue.5
, pp. 525-540
-
-
Dowman, J.K.1
Tomlinson, J.W.2
Newsome, P.N.3
-
95
-
-
79959573040
-
Endpoints and clinical trial design for nonalcoholic steatohepatitis
-
Sanyal A.J., et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011, 54(1):344-353.
-
(2011)
Hepatology
, vol.54
, Issue.1
, pp. 344-353
-
-
Sanyal, A.J.1
-
96
-
-
84890469071
-
Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease
-
Martín-Domínguez Verónica, G.-C.R., Mendoza-Jiménez-Ridruejo J., García-Buey Luisa, Moreno-Otero Ricardo Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease. Rev. Esp. Enferm. Dig. 2013, 105:409-420.
-
(2013)
Rev. Esp. Enferm. Dig.
, vol.105
, pp. 409-420
-
-
Martín-Domínguez, Verónica1
G.-C.R.2
Mendoza-Jiménez-Ridruejo, J.3
García-Buey, L.4
Moreno-Otero, R.5
-
97
-
-
72449161164
-
Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults
-
Shah K., et al. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009, 17(12):2162-2168.
-
(2009)
Obesity (Silver Spring)
, vol.17
, Issue.12
, pp. 2162-2168
-
-
Shah, K.1
-
98
-
-
0025186310
-
Effect of weight reduction on hepatic abnormalities in overweight patients
-
Palmer M., Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99(5):1408-1413.
-
(1990)
Gastroenterology
, vol.99
, Issue.5
, pp. 1408-1413
-
-
Palmer, M.1
Schaffner, F.2
-
99
-
-
2442615980
-
Alow-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial
-
Yancy W.S., et al. Alow-carbohydrate, ketogenic diet versus a low-fat diet to treat obesity and hyperlipidemia: a randomized, controlled trial. Ann. Intern Med. 2004, 140(10):769-777.
-
(2004)
Ann. Intern Med.
, vol.140
, Issue.10
, pp. 769-777
-
-
Yancy, W.S.1
-
100
-
-
73449116035
-
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis
-
Promrat K., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
-
(2010)
Hepatology
, vol.51
, Issue.1
, pp. 121-129
-
-
Promrat, K.1
-
101
-
-
84925362378
-
Moderate to vigorous physical activity volume is an important factor for managing non-alcoholic fatty liver disease: a retrospective study
-
(Epub ahead of print)
-
Oh S., et al. Moderate to vigorous physical activity volume is an important factor for managing non-alcoholic fatty liver disease: a retrospective study. Hepatology 2014, (Epub ahead of print). 10.1002/hep.27544.
-
(2014)
Hepatology
-
-
Oh, S.1
-
102
-
-
33646483917
-
Adouble-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
-
Zelber-Sagi S., et al. Adouble-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006, 4(5):639-644.
-
(2006)
Clin. Gastroenterol. Hepatol.
, vol.4
, Issue.5
, pp. 639-644
-
-
Zelber-Sagi, S.1
-
103
-
-
0030147221
-
Adouble-blind randomized placebo-controlled trial of sibutramine
-
Bray G.A., et al. Adouble-blind randomized placebo-controlled trial of sibutramine. Obes. Res. 1996, 4(3):263-270.
-
(1996)
Obes. Res.
, vol.4
, Issue.3
, pp. 263-270
-
-
Bray, G.A.1
-
104
-
-
0034516930
-
Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance
-
James W.P., et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000, 356(9248):2119-2125.
-
(2000)
Lancet
, vol.356
, Issue.9248
, pp. 2119-2125
-
-
James, W.P.1
-
105
-
-
79959466159
-
Current therapeutic strategies in non-alcoholic fatty liver disease
-
Dowman J.K., et al. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes. Metab. 2011, 13(8):692-702.
-
(2011)
Diabetes Obes. Metab.
, vol.13
, Issue.8
, pp. 692-702
-
-
Dowman, J.K.1
-
106
-
-
77956284607
-
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
-
James W.P., et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N.Engl. J. Med. 2010, 363(10):905-917.
-
(2010)
N.Engl. J. Med.
, vol.363
, Issue.10
, pp. 905-917
-
-
James, W.P.1
-
107
-
-
33751001942
-
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study
-
Scheen A.J., et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368(9548):1660-1672.
-
(2006)
Lancet
, vol.368
, Issue.9548
, pp. 1660-1672
-
-
Scheen, A.J.1
-
108
-
-
32644441249
-
Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial
-
Pi-Sunyer F.X., et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295(7):761-775.
-
(2006)
JAMA
, vol.295
, Issue.7
, pp. 761-775
-
-
Pi-Sunyer, F.X.1
-
109
-
-
17144382751
-
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
-
Van Gaal L.F., et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365(9468):1389-1397.
-
(2005)
Lancet
, vol.365
, Issue.9468
, pp. 1389-1397
-
-
Van Gaal, L.F.1
-
110
-
-
77956017429
-
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
-
Topol E.J., et al. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet 2010, 376(9740):517-523.
-
(2010)
Lancet
, vol.376
, Issue.9740
, pp. 517-523
-
-
Topol, E.J.1
-
111
-
-
57149101692
-
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis
-
Mummadi R.R., et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2008, 6(12):1396-1402.
-
(2008)
Clin. Gastroenterol. Hepatol.
, vol.6
, Issue.12
, pp. 1396-1402
-
-
Mummadi, R.R.1
-
112
-
-
0034773404
-
Role of AMP-activated protein kinase in mechanism of metformin action
-
Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J.Clin. Invest 2001, 108(8):1167-1174.
-
(2001)
J.Clin. Invest
, vol.108
, Issue.8
, pp. 1167-1174
-
-
Zhou, G.1
-
113
-
-
84903273250
-
AMPK activation: a therapeutic target for type 2 diabetes?
-
Coughlan K.A., et al. AMPK activation: a therapeutic target for type 2 diabetes?. Diabetes Metab. Syndr. Obes. 2014, 7:241-253.
-
(2014)
Diabetes Metab. Syndr. Obes.
, vol.7
, pp. 241-253
-
-
Coughlan, K.A.1
-
114
-
-
84920155380
-
Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis
-
Li Y., et al. Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Biomed. Rep. 2013, 1(1):57-64.
-
(2013)
Biomed. Rep.
, vol.1
, Issue.1
, pp. 57-64
-
-
Li, Y.1
-
115
-
-
84862517200
-
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
-
Musso G., et al. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia 2012, 55(4):885-904.
-
(2012)
Diabetologia
, vol.55
, Issue.4
, pp. 885-904
-
-
Musso, G.1
-
116
-
-
1642302410
-
Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men
-
Zanchi A., et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J.Clin. Endocrinol. Metab. 2004, 89(3):1140-1145.
-
(2004)
J.Clin. Endocrinol. Metab.
, vol.89
, Issue.3
, pp. 1140-1145
-
-
Zanchi, A.1
-
117
-
-
34547700735
-
Thiazolidinediones and heart failure: a teleo-analysis
-
Singh S., Loke Y.K., Furberg C.D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007, 30(8):2148-2153.
-
(2007)
Diabetes Care
, vol.30
, Issue.8
, pp. 2148-2153
-
-
Singh, S.1
Loke, Y.K.2
Furberg, C.D.3
-
118
-
-
33751545838
-
Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
-
Belfort R., et al. Aplacebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N.Engl. J. Med. 2006, 355(22):2297-2307.
-
(2006)
N.Engl. J. Med.
, vol.355
, Issue.22
, pp. 2297-2307
-
-
Belfort, R.1
-
119
-
-
77951874018
-
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
-
Sanyal A.J., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N.Engl. J. Med. 2010, 362(18):1675-1685.
-
(2010)
N.Engl. J. Med.
, vol.362
, Issue.18
, pp. 1675-1685
-
-
Sanyal, A.J.1
-
120
-
-
0035462466
-
Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men
-
Rask E., et al. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001, 24(9):1640-1645.
-
(2001)
Diabetes Care
, vol.24
, Issue.9
, pp. 1640-1645
-
-
Rask, E.1
-
121
-
-
0038121744
-
Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
-
Vilsboll T., et al. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul. Pept. 2003, 114(2-3):115-121.
-
(2003)
Regul. Pept.
, vol.114
, Issue.2-3
, pp. 115-121
-
-
Vilsboll, T.1
-
122
-
-
84902661992
-
Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease
-
Blaslov K., et al. Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(23):7356-7365.
-
(2014)
World J. Gastroenterol.
, vol.20
, Issue.23
, pp. 7356-7365
-
-
Blaslov, K.1
-
123
-
-
34249869806
-
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes
-
Vilsboll T., et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30(6):1608-1610.
-
(2007)
Diabetes Care
, vol.30
, Issue.6
, pp. 1608-1610
-
-
Vilsboll, T.1
-
124
-
-
0038497464
-
Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes
-
Kolterman O.G., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J.Clin. Endocrinol. Metab. 2003, 88(7):3082-3089.
-
(2003)
J.Clin. Endocrinol. Metab.
, vol.88
, Issue.7
, pp. 3082-3089
-
-
Kolterman, O.G.1
-
125
-
-
84902687972
-
Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus
-
Fukuhara T., et al. Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014, 61(130):323-328.
-
(2014)
Hepatogastroenterology
, vol.61
, Issue.130
, pp. 323-328
-
-
Fukuhara, T.1
-
126
-
-
33845472504
-
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
-
Aschner P., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29(12):2632-2637.
-
(2006)
Diabetes Care
, vol.29
, Issue.12
, pp. 2632-2637
-
-
Aschner, P.1
-
127
-
-
70349333861
-
Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
-
Rosenstock J., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr. Med. Res. Opin. 2009, 25(10):2401-2411.
-
(2009)
Curr. Med. Res. Opin.
, vol.25
, Issue.10
, pp. 2401-2411
-
-
Rosenstock, J.1
-
128
-
-
33947156808
-
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
-
Buse J.B., et al. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin. Ther. 2007, 29(1):139-153.
-
(2007)
Clin. Ther.
, vol.29
, Issue.1
, pp. 139-153
-
-
Buse, J.B.1
-
129
-
-
79955446251
-
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial
-
Lavine J.E., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011, 305(16):1659-1668.
-
(2011)
JAMA
, vol.305
, Issue.16
, pp. 1659-1668
-
-
Lavine, J.E.1
-
130
-
-
84862636851
-
Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
-
Beaton M.D. Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Can. J. Gastroenterol. 2012, 26(6):353-357.
-
(2012)
Can. J. Gastroenterol.
, vol.26
, Issue.6
, pp. 353-357
-
-
Beaton, M.D.1
-
131
-
-
73149092115
-
Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial
-
Abdelmalek M.F., et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial. Hepatology 2009, 50(6):1818-1826.
-
(2009)
Hepatology
, vol.50
, Issue.6
, pp. 1818-1826
-
-
Abdelmalek, M.F.1
-
132
-
-
77955699301
-
High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial
-
Leuschner U.F., et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52(2):472-479.
-
(2010)
Hepatology
, vol.52
, Issue.2
, pp. 472-479
-
-
Leuschner, U.F.1
-
133
-
-
1542515099
-
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial
-
Lindor K.D., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39(3):770-778.
-
(2004)
Hepatology
, vol.39
, Issue.3
, pp. 770-778
-
-
Lindor, K.D.1
-
134
-
-
84900451257
-
Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies
-
Zeng T., et al. Pentoxifylline for the treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized double-blind, placebo-controlled studies. Eur. J. Gastroenterol. Hepatol. 2014, 26(6):646-653.
-
(2014)
Eur. J. Gastroenterol. Hepatol.
, vol.26
, Issue.6
, pp. 646-653
-
-
Zeng, T.1
-
135
-
-
84912096773
-
Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease
-
Paolella G., et al. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. World J. Gastroenterol. 2014, 20(42):15518-15531.
-
(2014)
World J. Gastroenterol.
, vol.20
, Issue.42
, pp. 15518-15531
-
-
Paolella, G.1
-
136
-
-
84886999533
-
Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis
-
Ma Y.Y., et al. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J. Gastroenterol. 2013, 19(40):6911-6918.
-
(2013)
World J. Gastroenterol.
, vol.19
, Issue.40
, pp. 6911-6918
-
-
Ma, Y.Y.1
-
137
-
-
84900032263
-
Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis
-
Alisi A., et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2014, 39(11):1276-1285.
-
(2014)
Aliment. Pharmacol. Ther.
, vol.39
, Issue.11
, pp. 1276-1285
-
-
Alisi, A.1
-
138
-
-
84856763599
-
Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis
-
Malaguarnera M., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis. Dig. Dis. Sci. 2012, 57(2):545-553.
-
(2012)
Dig. Dis. Sci.
, vol.57
, Issue.2
, pp. 545-553
-
-
Malaguarnera, M.1
-
139
-
-
84857802209
-
Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis
-
Newsome P.N., et al. Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012, 61(4):484-500.
-
(2012)
Gut
, vol.61
, Issue.4
, pp. 484-500
-
-
Newsome, P.N.1
|